Text Size

Chinese Network of Pediatric Antiretroviral Therapy (CN-PART)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2010 by National Center for AIDS/STD Control and Prevention, China CDC.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Center for AIDS/STD Control and Prevention, China CDC
ClinicalTrials.gov Identifier:
NCT01210924
First received: September 27, 2010
Last updated: NA
Last verified: September 2010
History: No changes posted
  Purpose

This is an observational cohort in pediatric HIV patients in China. Children who receive antiretroviral drugs will be recruited in this study. The main objectives are as follows: 1. To establish simpler and smarter pediatric antiretroviral therapy in China including both first-line and second-line regimens. 2. To study the nature, characteristics and mechanisms of immunoreconstitution in HIV-infected children using the data and samples from the pediatric antiretroviral therapy cohort. 3. To establish a basic science and clinical research network based on the pediatric antiretroviral cohort.


Condition
Acquired Immunodeficiency Syndrome

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Chinese Study of Pediatric Antiretroviral Therapy

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Further study details as provided by National Center for AIDS/STD Control and Prevention, China CDC:

Biospecimen Retention:   Samples With DNA

plamsa, PMBC, whole blood


Estimated Enrollment: 400
Study Start Date: April 2010
Groups/Cohorts
Pediatric ART patients

  Eligibility

Ages Eligible for Study:   up to 15 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Pediatric HIV-infected patients receiving triple antiretroviral drugs

Criteria

Inclusion Criteria:

  • clinical diagnosis of HIV infection
  • receiving triple antiretroviral drugs

Exclusion Criteria:

  • clinical status not stable
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01210924

Contacts
Contact: Fujie Zhang, MD +861063039086 treatment@chinaaids.cn
Contact: Yan Zhao, MD +861063039075 zhaoyanmgl@yahoo.com.cn

Locations
China
National Center for AIDS/STD Control and Prevention, China Center for Disease Control and Prevention Recruiting
Beijing, China, 102206
Contact: Yan Zhao, MD     +861063039075     zhaoyanmgl@yahoo.com.cn    
Principal Investigator: Fujie Zhang, MD            
Sponsors and Collaborators
National Center for AIDS/STD Control and Prevention, China CDC
Investigators
Principal Investigator: Fujie Zhang, MD National Center for AIDS/STD control and prevention
  More Information

No publications provided

Responsible Party: Dr. Fujie Zhang, National center for AIDS/STD control and prevention, National center for disease control and prevention
ClinicalTrials.gov Identifier: NCT01210924     History of Changes
Other Study ID Numbers: Pediatric treatment 2010, 2008ZX10001-007
Study First Received: September 27, 2010
Last Updated: September 27, 2010
Health Authority: China: Ministry of Health

Keywords provided by National Center for AIDS/STD Control and Prevention, China CDC:
children
Acquired Immunodeficiency Syndrome
antiretroviral therapy
China
Mortality

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
 Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on May 19, 2013